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Background: Percutaneous positioning of closure devices is a well-established treatment of atrial septal defects (ASD). Atrial fibrillation (AF) is 
highly prevalent in these pts, and it is unclear whether ASD closure might affect the progression of AF in pts presenting with concomitant ASD and AF. 
We report the long-term effect of transcatheter closure of ASD on the progression of AF, and the acute and long-term results of catheter ablation of 
AF in these pts.
Methods: 39 pts (age 51 ± 5 years) with ASD and history of AF (62% paroxysmal, 36% persistent, 2% long-standing persistent) underwent ASD 
closure with transcatheter implantable devices (82% Amplatzer®, 18% Cardioseal®).
Results: After a mean of 46 (6-82) months after ASD closure, all pts experienced significant progression of AF (11 progressed from paroxysmal to 
persistent AF, and 5 from persistent to long-standing persistent AF), becoming highly symptomatic, drug-refractory, and were referred for catheter 
ablation. In 35 (90%) pts the transseptal access was obtained in a portion of the native septum as detected by intracardiac echocardiography, while 
in 4 (10%) a direct access through the device was required. The latter group had a significantly longer time for achieving the double transseptal 
access (73.6±1.1 vs. 4.3±0.4 min, p<0.001) and longer fluoroscopy time (122±5 vs. 80±8 min, p<0.001). No periprocedural complication was 
observed. At a follow-up of 14±4 months the overall success rate was 77% (85% in paroxysmal AF, 73% in non-paroxysmal AF). Transthoracic 
contrast-enhanced echocardiography with the Valsalva maneuver, performed 3 to 6 months after the procedure, failed to detect shunt in all pts.
Conclusions: Device closure of ASD does not protect against the progression of AF in pts presenting with concomitant ASD and AF. Radiofrequency 
catheter ablation in these pts is feasible, safe and effective. Transseptal access can be obtained in portions of the native septum in the majority of 
the cases. Direct transseptal puncture of the device is feasible and safe, but it requires longer time for each transseptal access. An early intervention 
with catheter ablation before the implant of ASD device in pts with concomitant AF is also justifiable.
